The CNPG-backed oncology therapy developer boosted its overall funding to $70m in a round backed by Eli Lilly and CICC Capital.

China-based oncology drug developer Abbisko Therapeutics has secured $42m in series B funding from investors including Lilly Asia Ventures, a corporate venture capital subsidiary of pharmaceutical firm Eli Lilly, CenturyBio has reported.

Venture capital firm Qiming Ventures led the round, which included private equity investment manager Loyal Valley Capital, VC firm TF Capital Investments, an unnamed sovereign wealth fund and CICC Capital, a subsidiary of financial services firm China International Capital Corp.

Abbisko Therapeutics is developing small-molecule treatments for cancers…